APGE
NASDAQApogee Therapeutics Inc.
Price$134.00-0.03 (-0.02%)
01:30 PM07:45 PM
News · 26 weeks87+20%
2026-01-182026-07-12
Mix4690d
- Insider17(37%)
- SEC Filings17(37%)
- Other8(17%)
- Earnings3(7%)
- Analyst1(2%)
Latest news
25 items- INSIDERChief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form DEFM14A filed by Apogee Therapeutics Inc.DEFM14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERChief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- INSIDERChief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form PREM14A filed by Apogee Therapeutics Inc.PREM14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERChief Medical Officer Dambkowski Carl sold $3,500,640 worth of shares (26,400 units at $132.60) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 179,248 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Executive Officer Henderson Michael Thomas sold $10,603,200 worth of shares (80,000 units at $132.54) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 1,015,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apogee Therapeutics Inc.SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 144 filed by Apogee Therapeutics Inc.144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 8-K filed by Apogee Therapeutics Inc.8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioProposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie
- INSIDERChief Executive Officer Henderson Michael Thomas sold $1,667,622 worth of shares (20,000 units at $83.38) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,095,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Shah Nimish P4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Mckenna Mark C.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones William A Jr4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Fox Jennifer A.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
APGE FAQ
6 questionsWhere does APGE stock trade?
Apogee Therapeutics Inc. (APGE) is listed on NASDAQ.What sector and industry is APGE in?
Apogee Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Apogee Therapeutics Inc. go public?
Apogee Therapeutics Inc. (APGE) completed its IPO in 2023.What are analysts saying about APGE?
Apogee Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Buy on 2026-05-01.What companies are similar to APGE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare APGE side-by-side with any of them on Quantisnow.How can I track APGE on Quantisnow?
Quantisnow aggregates Apogee Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APGE to receive live email and push alerts on every new disclosure.